NYXOID

This brand name is authorized in Australia, Austria, Croatia, Estonia, France, Ireland, Italy, Lithuania, New Zealand, Poland, Romania, Spain, UK.

Active ingredients

The drug NYXOID contains one active pharmaceutical ingredient (API):

1	Naloxone UNII 5Q187997EE - NALOXONE HYDROCHLORIDE DIHYDRATE
	Naloxone hydrochloride, a semisynthetic morphine derivative (N-allyl-nor-oxymorphone), is a specific opioid antagonist that acts competitively at opioid receptors. It reveals very high affinity for the opioid receptor sites and therefore displaces both opioid agonists and partial antagonists, such as pentazocine, for example, but also nalorphine.
	Read more about Naloxone

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
NYXOID Nasal spray	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
V03AB15	Naloxone	V Various → V03 All other therapeutic products → V03A All other therapeutic products → V03AB Antidotes
Discover more medicines within V03AB15

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	11816X, 11817Y
EE	Ravimiamet	1756773
ES	Centro de información online de medicamentos de la AEMPS	1171238001
FR	Base de données publique des médicaments	63868145
GB	Medicines & Healthcare Products Regulatory Agency	357442
IT	Agenzia del Farmaco	045777012
LT	Valstybinė vaistų kontrolės tarnyba	1084451
NZ	Medicines and Medical Devices Safety Authority	20367, 21656
PL	Rejestru Produktów Leczniczych	100399996
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W66685001